The pieces of the puzzle continue to drop into place for Cellceutix Corporation (OTCBB:CTIX).  News hit this morning that Dr. Paul Marks has joined the Cellceutix Scientific Advisory Board.  Additionally corporate intellectual property (IP) will be further safeguarded as the Company reported filing foreign patent applications relating to pharmaceutical compositions comprising its anti-cancer compound Kevetrin™.  These applications are based on the earlier International Application filed under the Patent Cooperation Treaty in 2009.

A bit about Dr. Paul Marks:

• Served as President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center (“MSKCC”) from 1980 to 1999
• Presently serving as President Emeritus and Member of the Sloan-Kettering Institute
• Member of the National Academy of Sciences and the Institute of Medicine
• Fellow at the American Academy of Arts and Sciences
• Professor of Human Genetics and Frode Jensen Professor of Medicine (1968-1980), Dean of the Faculty of Medicine (1970-1973), and Vice President for Health Sciences and Director of the Comprehensive Cancer Center (1973-1980) at Columbia University
• Earned his AB and MD degrees from Columbia University and postdoctoral training at the National Institutes of Health and the Pasteur Institute
• Published more than 350 scientific articles in various scholarly journals.

Memorial Sloan-Kettering Cancer Center honored the accomplishments of Dr. Marks with the creation of The Paul Marks Prize for Cancer Research, an award that it bestows upon up to three investigators every other year to recognize new leaders in cancer research.

Regarding their IP, the applications were filed under the direction of John Richards of the preeminent international intellectual property law firm Ladas & Parry. Mr. Richards is one of the leading worldwide experts on international pharmaceutical and chemical patents, having represented numerous large corporations on cases of major commercial significance.

Commenting on the recent developments, Cellceutix Chief Scientific Officer Dr. Krishna Menon stated,

We are extremely pleased to add Dr. Marks to our team.  We have assembled a world-class advisory board with Dr. Emil Frei, Dr. Samuel Danishefsky, Dr. Paul Ginsburg and now Dr. Paul Marks. Going forward with Kevetrin™ in clinical trials, as well as other drugs in our pipeline, their experience and knowledge will play a key role in our success. I wish to add that I have never been as excited about a cancer compound as I am now with Kevetrin™. Everything is coming together very nicely. It is indeed a very exciting time for Cellceutix and its shareholders.

Cellceutix Corporation (CTIX) Stock Quote and News:

---

Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated on several occasions for news dissemination and journalism services from Cellceutix Corporation and holds a total of 100,000 shares of 144 restricted stock of Cellceutix Corporation, none of which has been sold to date, nor intends to be sold in the near term. Prior compensation is listed in our full disclosure. Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/?page_id=190.